Price Vision Group clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   Corneal Crosslinking · Corneal Neovascularization

   Primary completion pushed from Jul 15, 2026 to Jul 15, 2029

   Also in this update: Enrollment increased: 62 → 138 participants; Study completion pushed from Sep 15, 2026 to Sep 15, 2029

   Price Vision Group·Phase 2/3· NCT04787471· Registry history of NCT04787471 on ClinicalTrials.gov (opens the registry)

   Updated Sep 17, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.